CRGX (Cargo Therapeutics) Interest Expense : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cargo Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cargo Therapeutics's interest expense for the three months ended in Dec. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cargo Therapeutics's Operating Income for the three months ended in Dec. 2024 was $ -50.13 Mil. Cargo Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $ 0.00 Mil. GuruFocus does not calculate Cargo Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cargo Therapeutics Interest Expense Historical Data

The historical data trend for Cargo Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cargo Therapeutics Interest Expense Chart

Cargo Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Interest Expense

-4.94

-1.60

Cargo Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial						-	-	-	-	-

Cargo Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Cargo Therapeutics (NAS:CRGX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cargo Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-50.13 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $28.80 Mil.

Cargo Therapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate Cargo Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Cargo Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Cargo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cargo Therapeutics Inc (NAS:CRGX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.cargo-tx.com

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.